Article

Serum Zinc Level and non-Protein Respiratory Quotient in Patients with Chronic Liver Diseases

Hiroki Nishikawa *, Ryo Takata, Hirayuki Enomoto, Kazunori Yoh, Yoshinori Iwata, Yoshiyuki Sakai, Kyohei Kishino, Yoshihiro Shimono, Naoto Ikeda, Tomoyuki Takashima, Nobuhiro Aizawa, Kunihiro Hasegawa, Noriko Ishii, Yukihsia Yuri, Takashi Nishimura, Hiroko Iijima and Shuhei Nishiguchi

Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan; chano_chano_rt@yahoo.co.jp (R.T.); enomoto@hyo-med.ac.jp (H.E.); mm2wintwin@ybb.ne.jp (K.Y.); yo-iwata@hyo-med.ac.jp (Y.I.); sakai429@hyo-med.ac.jp (Y.S.); hcm.kyohei@gmail.com (K.K.); yoshihiro19870729@yahoo.co.jp (Y.S.); nikeneko@hyo-med.ac.jp (N.I.); tomo0204@yahoo.co.jp (T.T.); nobu23hiro@yahoo.co.jp (N.A.); hiro.red1230@gmail.com (K.H.); ishinori1985@yahoo.co.jp (N.I.); gyma27ijo04td@gmail.com (Y.Y.); tk-nishimura@hyo-med.ac.jp (T.N.); hiroko-i@hyo-med.ac.jp (H.I.); nishiguc@hyo-med.ac.jp (S.N.)

* Correspondence: nishikawa_6392_0207@yahoo.co.jp; Tel.: +81-798-45-6472

Received: 22 December 2019; Accepted: 15 January 2020; Published: 17 January 2020

Abstract: We sought to clarify the correlation between non-protein respiratory quotient (npRQ) in indirect calorimetry and serum zinc (Zn) level in chronic liver diseases (CLDs, n = 586, 309 liver cirrhosis (LC) patients, median age = 63 years). Clinical parameters potentially linked to npRQ <0.85 (best cutoff point for the prognosis in LC patients) were also examined in receiver operating characteristic curve (ROC) analyses. The median npRQ was 0.86. The median serum Zn level was 64 µg/dL. The median npRQ in patients with non-LC, Child–Pugh A, Child–Pugh B and Child–Pugh C were 0.89, 0.85, 0.83 and 0.82 (overall p < 0.0001). The median serum Zn level in patients with npRQ <0.85 (58 µg/dL) was significantly lower than that in patients with npRQ ≥ 0.85 (68 µg/dL) (p < 0.0001). The correlation coefficient (r) between npRQ level and serum Zn level for all cases was 0.40 (p < 0.0001). Similar tendencies were observed in all subgroup analyses. The highest correlation coefficient between serum Zn level and npRQ was found in patients with Child–Pugh C (n = 22, r = 0.69). In ROC analyses for npRQ <0.85, serum Zn level had the highest area under the ROC (AUC) among baseline laboratory parameters (AUC = 0.69). In conclusion, serum Zn level can be helpful for npRQ in patients with CLDs.

Keywords: chronic liver disease; non-protein respiratory quotient; zinc; indirect calorimetry; correlation

1. Introduction

The liver is a key player for the metabolism and preservation of nutrients, and its deep involvement can be seen in the maintenance of serum blood glucose levels or gluconeogenesis from glycojen etc [1–3]. Liver cirrhosis (LC), which can develop due to persistent inflammation over a long period of time in the liver, is frequently accompanied by protein-energy malnutrition (PEM) [1,2,4–7]. Assessment methods for protein malnutrition and energy malnutrition are in general serum albumin level and the non-protein respiratory quotient (npRQ) in indirect calorimetry (IC, metabolic cart) [8]. RQs suggest which macronutrients (i.e., carbohydrates, protein or fat) are being metabolized: RQ value which approaches 1.0 denotes that carbohydrates are mainly being consumed as an energy source and RQ value which approaches 0.7 denotes that fats are being consumed as an energy source [9].
RQ value can exceed 1.00 during hard exercise [9]. npRQ indicates RQ excluding protein burning [8]. PEM is a common disorder identified in LC patients, which can cause worse clinical outcomes in LC patients [1,2,4–6,8,10,11]. In our previous study, we demonstrated the significant correlation between npRQ level and albumin-bilirubin (ALBI) grade, which can be an alternative classification system for Child–Pugh classification, in patients with chronic liver diseases (CLDs) [12,13].

Zinc (Zn) is widely distributed in the human body, being a key trace element for normal cell growth and normal cell differentiation [14]. Zn is essential for the catalytic activity of numerous enzymes involved in energy nutrition metabolism and seems to regulate several hormones which play important roles in the metabolism [15]. Zn deficiency is a major health issue worldwide and causes numerous clinical symptoms [16–19]. The homeostasis of Zn is primarily regulated in the liver and the degree of Zn loss in CLD patients has been shown to be well correlated with the liver diseases severity [20–25]. In our recent reports, we have shown the close relationship between serum Zn level and sarcopenia as defined by low muscle strength and low skeletal muscle decline in CLD patients [26]. Sarcopenia in CLDs can be linked to the liver diseases severity [27]. However, the relationship between npRQ level in IC and serum Zn level in CLD patients has been largely unknown. To elucidate the issue seems to be clinically of importance because IC is expensive and involves time-consuming procedures, while serum Zn level can be obtained easily in the clinical settings [28,29]. In the current study, we sought to clarify this important research question.

2. Patients and Methods

2.1. Patients

A total of 601 CLD patients with data for npRQ in IC available were admitted to our hospital between October 2005 and August 2018. Of these, 15 patients had missing data for serum Zn level. A total of 586 CLD patients having data for both npRQ in IC and serum Zn level were thus subjected to the current analysis. Liver histological data (F0–F4) were available in all analyzed patients and bioimpedance analysis (BIA) data were available in 580 patients (99.0%).

2.2. Measurement of npRQ by IC

Oxygen consumption in one minute (VO$_2$) and carbon dioxide production in one minute (VCO$_2$) were tested by IC. As explained in the introduction section, npRQ indicates RQ excluding protein burning. Total urinary nitrogen excretion (UN) was measured as reported elsewhere [8,30]. npRQ was calculated by the formula as reported previously [6,25].

2.3. SMI and ECW to TBW Ratio using BIA

The definition of skeletal muscle index (SMI) is “appendicular skeletal muscle mass (SMM) divided by height squared (kg/m$^2$)” in BIA. Referring to the current Japanese criteria, the definition of SMM loss was: SMI < 7.0 kg/m$^2$ in men and <5.7 kg/m$^2$ in women [27]. Considering the fact that excessive extracellular water (ECW) results in edematous condition, extracellular fluid (ECF) status was considered to correspond to the ECW to total body water (TBW) ratio (ECW/TBW). In healthy individuals, ECW/TBW is able to be kept at a constant level (around 0.38). ECF excess was categorized into the following three conditions referring to ECW/TBW: normal condition (<0.390), mild overhydrated condition (0.390–0.399) and moderate to severe overhydrated condition (≥0.400) [31].

The relationship between npRQ and serum Zn level, and clinical parameters potentially linked to npRQ < 0.85 (best cutoff value for clinical outcomes in LC patients) was studied in receiver operating characteristic curve (ROC) analyses [8,28,32]. This study was done per the ethical principles of the 1975 Declaration of Helsinki and was approved by the institutional review board in Hyogo college of medicine hospital (approval no.1831).
2.4. Statistical Considerations

In the analysis of continuous variables, for the purpose of assessing between-group difference, Student’s *t* test, Mann–Whitney *U* test, Pearson’s correlation coefficient *r*, analysis of variance or Kruskal-Wallis test were in employment as applicable. ROC analysis was done for calculating the area under the ROC (AUC) for laboratory parameters choosing the optimal cutoff value that maximized the total value of sensitivity and specificity for npRQ <0.85. Clinical data were shown as median value (interquartile range (IQR)). A *p* < 0.05 was considered statistical significance. The JMP 14 (SAS Institute Inc., Cary, NC) was in employment for statistical analysis.

3. Results

3.1. Patient Baseline Backgrounds

Patient baseline backgrounds in the study (*n* = 586, 290 men and 296 women, median (IQR) age = 63 (54,71) years) are shown in Table 1. The median (IQR) npRQ was 0.86 (0.82, 0.93). Two hundred and forty-two patients (41.3%) had npRQ <0.85. The median (IQR) serum Zn level was 64 µg/dL (55, 73 µg/dL). In terms of cause for liver disease, 309 patients (52.7%) had hepatitis C virus (HCV). In terms of the severity of liver fibrosis (F factor), there were 12 patients in F0, 113 in F1, 77 in F2, 75 in F3 and 309 in F4. In LC patients (*n* = 309), Child–Pugh A was found in 169 patients, Child–Pugh B in 118 and Child–Pugh C in 22. The median (IQR) npRQ in patients with chronic hepatitis (non-LC), Child–Pugh A, Child–Pugh B and Child–Pugh C were: 0.89 (0.83, 0.95), 0.85 (0.81, 0.9), 0.83 (0.80, 0.89) and 0.82 (0.7775, 0.8725) (*p* values: CH versus Child–Pugh A, *p* < 0.0001; Child–Pugh A versus Child–Pugh B, *p* = 0.3008; Child–Pugh B versus Child–Pugh C, *p* = 0.2020; CH versus Child–Pugh B, *p* < 0.0001; CH versus Child–Pugh C, *p* < 0.0001; Child–Pugh A versus Child–Pugh C, *p* = 0.0552; (overall *p* < 0.0001)). (Figure 1) Hepatocellular carcinoma (HCC) was found in 161 patients (27.5%). Ascites was identified in 50 patients (8.5%). The median (IQR) npRQ in patients with HCC and without HCC were: 0.84 (0.80, 0.90) and 0.87 (0.82, 0.94) (*p* = 0.0074). The median (IQR) npRQ in patients with ascites and without ascites were: 0.82 (0.78, 0.85) and 0.87 (0.82, 0.93) (*p* < 0.0001).

**Table 1.** Baseline data (*n* = 586).

| Parameters                                      | Number or Median (Interquartile Range) |
|------------------------------------------------|---------------------------------------|
| Gender, male/female                             | 290/296                               |
| Age (years)                                     | 63 (54, 71)                           |
| Body mass index (kg/m²)                         | 22.2 (20.2, 24.9)                     |
| Presence of LC, yes/no                          | 309/277                               |
| Child–Pugh A, B and C (LC patients)             | 169/118/22                           |
| Presence of HCC, yes/no/unknown                 | 161/422/3                             |
| Ascites, yes/no/unknown                         | 50/533/3                              |
| Skeletal muscle mass index (kg/m²), male        | 7.3 (6.8, 8.0)                        |
| Skeletal muscle mass index (kg/m²), female      | 5.8 (5.3, 6.3)                        |
| ECW to TBW ratio                                | 0.385 (0.376, 0.393)                  |
| Causes of liver disease                         |                                       |
| Hepatitis B/Hepatitis C/alcohol/NAFLD or NASH/AIH or PBC/others | 62/309/44/71/71/29                   |
| Liver histology                                 | 12/113/77/75/309                      |
| F0/F1/F2/F3/F4                                  | 0.86 (0.82, 0.93)                     |
| npRQ                                           |                                       |
| Total bilirubin (mg/dL)                         | 0.9 (0.7, 1.3)                        |
Table 1. Cont.

| Parameters                        | Number or Median (Interquartile Range) |
|-----------------------------------|----------------------------------------|
| Serum albumin (g/dL)              | 3.8 (3.3, 4.1)                          |
| Prothrombin time (%)              | 86.0 (72, 95.4)                         |
| Platelets (x10^4/mm^3)            | 12.3 (7.8, 19.0)                       |
| Total cholesterol (mg/dl)         | 160 (135, 188)                         |
| AST (IU/L)                        | 39.5 (28, 62)                           |
| ALT (IU/L)                        | 35.5 (23, 62)                           |
| Serum zinc (µg/dL)                | 64 (55, 73)                             |
| HbA1c (NGSP)                      | 5.2 (4.9, 5.7)                          |
| Branched-chain amino acid to tyrosine ratio | 5.04 (3.73, 6.335)                 |

LC; liver cirrhosis, HCC; hepatocellular carcinoma, ECW; extracellular water, TBW; total body water, NAFLD; non-alcoholic fatty liver disease, NASH; non-alcoholic steatohepatitis, AIH; autoimmune hepatitis, PBC; primary biliary cholangitis, npRQ; non-protein respiratory quotient, AST; aspartate aminotransferase, ALT; alanine aminotransferase, NGSP; National Glycohemoglobin Standardization Program.

**Figure 1.** Comparison of npRQ (non-protein respiratory quotient) level in patients with chronic hepatitis (non-LC; non-liver cirrhosis), Child–Pugh A, Child–Pugh B and Child–Pugh C.

### 3.2. Correlation between npRQ Level and Serum Zn Level for All Cases

The correlation coefficient (r) between npRQ level and serum Zn level was 0.40 (p < 0.0001). (Figure 2A) The median (IQR) serum Zn level in patients with npRQ < 0.85 (n = 242, 58 µg/dL (47, 66.25 µg/dL)) was significantly lower than that in patients with npRQ ≥ 0.85 (n = 344, 68 µg/dL (61, 75 µg/dL)) (p < 0.0001). (Figure 2B) Currently, the Japanese society of clinical nutrition (JSCN) defines the followings: (A) serum Zn level < 60 µg/dL corresponds to Zn deficiency; (B) 60 µg/dL ≤ serum Zn level < 80 µg/dL corresponds to subclinical Zn deficiency; and (C) 80 µg/dL ≤ serum Zn level < 130 µg/dL corresponds to normal Zn level [33]. The median npRQ levels in patients with Zn deficiency (n = 211), subclinical Zn deficiency (n = 305) and normal Zn range (n = 70) were: 0.82 (0.78, 0.86), 0.88 (0.84, 0.95) and 0.94 (0.8375, 1.01) (p < values: Zn deficiency versus subclinical Zn deficiency, p < 0.0001; subclinical Zn deficiency versus normal Zn level, p = 0.0038; Zn deficiency versus normal Zn level, p < 0.0001; overall p < 0.0001) (Figure 2C).
Figure 2. (A) Correlation between serum Zn level and npRQ (non-protein respiratory quotient) for all cases \((n = 586)\). (B) Comparison of serum Zn level stratified by npRQ level. (C) Comparison of npRQ level based on the serum Zn classification system proposed by the Japanese society of clinical nutrition.

3.3. Correlation npRQ Level and Serum Zn Level According to the LC Status and the Child–Pugh Classification

In LC patients, there was a significant correlation between serum Zn level and npRQ level \((r = 0.42, p < 0.0001)\) (Figure 3A). In non-LC patients, there was a significant correlation between serum Zn level and npRQ level \((r = 0.29, p < 0.0001)\) (Figure 3B).

Figure 3. (A,B) Correlation between serum Zn level and npRQ (non-protein respiratory quotient) in patients with LC (liver cirrhosis) and non-LC (non-liver cirrhosis). (C–E) Correlation between serum Zn level and npRQ in patients with Child–Pugh (A–C).
The median (IQR) serum Zn levels in patients with Child–Pugh A, B and C were 66 µg/dL (57.5, 72 µg/dL), 54 µg/dL (43.75, 60.4 µg/dL) and 38.05 µg/dL (30.75, 47.5 µg/dL). In Child–Pugh A, B and C patients, significant correlation was found between npRQ level and serum Zn level: Child–Pugh A, \( r = 0.46, p < 0.0001 \); Child–Pugh B, \( r = 0.37, p < 0.0001 \); Child–Pugh C, \( r = 0.69, p = 0.0004 \) (Figure 3C–E).

3.4. Correlation npRQ Level and Serum Zn Level According to the Body Mass Index (BMI) Value

The study population was divided into three groups based on the BMI value (\( n = 1 \)): BMI ≥ 25 kg/m\(^2\) (\( n = 142 \)), 25 kg/m\(^2\) > BMI ≥ 25 kg/m\(^2\) (\( n = 313 \)) and BMI < 20 kg/m\(^2\) (\( n = 130 \)). The correlation coefficients between npRQ level and serum Zn level in patients with BMI ≥ 25 kg/m\(^2\), 25 kg/m\(^2\) > BMI ≥ 25 kg/m\(^2\) and BMI < 20 kg/m\(^2\) were: \( r = 0.33 (p < 0.0001) \), \( r = 0.46 (p < 0.0001) \) and \( r = 0.37 (p < 0.0001) \) (Figure 4A–C).

![Figure 4. (A–C) Correlation between serum Zn level and npRQ according to the BMI status. (D,E) Correlation between serum Zn level and npRQ in patients with SMI decrease and SMI non-decrease.](image)

3.5. Correlation npRQ Level and Serum Zn Level According to the SMI Value

The study population was divided into two groups based on the SMI value (\( n = 6 \)): SMI decrease (\( n = 215 \)) and SMI non-decrease (\( n = 365 \)) using the Japanese guidelines [27]. The correlation coefficients between npRQ level and serum Zn level in patients with SMI decrease and SMI non-decrease were: \( r = 0.38 (p < 0.0001) \) and \( r = 0.45 (p < 0.0001) \) (Figure 4D,E).

3.6. Correlation npRQ Level and Serum Zn Level According to the ECW/TBW

The study population was divided into two groups based on the ECW/TBW (\( n = 6 \)): ECW/TBW ≥ 0.40 (\( n = 67 \)) and ECW/TBW < 0.40 (\( n = 513 \)). The correlation coefficients between npRQ level and serum Zn level in patients with ECW/TBW ≥ 0.40 and ECW/TBW < 0.40 were: \( r = 0.41 (p = 0.0006) \) and \( r = 0.41 (p < 0.0001) \) (Figure 5A,B).
3.7. Correlation npRQ Level and Serum Zn Level According to the Presence or Absence of HCC

The correlation coefficients between npRQ level and serum Zn level in patients with HCC and without HCC were: $r = 0.43 \ (p < 0.0001)$ and $r = 0.38 \ (p < 0.0001)$ (Figure 5C,D).

3.8. Correlation npRQ Level and Serum Zn Level According to the Liver Disease Etiologies

The correlation coefficients between npRQ level and serum Zn level in patients with hepatitis B virus ($n = 62$), HCV ($n = 309$), alcohol ($n = 44$), non-alcoholic fatty liver disease or non-alcoholic steatohepatitis ($n = 71$), and autoimmune hepatitis (AIH) or primary biliary cholangitis (PBC) ($n = 71$) were: $r = 0.43 \ (p = 0.0005)$, $r = 0.43 \ (p < 0.0001)$, $r = 0.48 \ (p = 0.0009)$, $r = 0.43 \ (p = 0.0002)$, and $r = 0.55 \ (p < 0.0001)$ (Figure 6A–E).
3.9. ROC Analyses for the npRQ < 0.85

Results of ROC analysis for the npRQ < 0.85 in baseline laboratory parameters are presented in Table 2. Serum Zn level had the highest AUC (0.69), followed by prothrombin time (AUC = 0.65). The AUCs, optimal cutoff points, sensitivity (%) and specificity (%) in each parameter are shown in Table 2.

Table 2. ROC analyses for npRQ < 0.85.

| Parameter         | AUC  | Sensitivity (%) | Specificity (%) | Cutoff Value |
|-------------------|------|-----------------|-----------------|--------------|
| Age               | 0.57 | 49.2            | 65.4            | 66.5         |
| Body mass index   | 0.56 | 48.4            | 66.5            | 23.1         |
| Serum zinc        | 0.69 | 62.2            | 60.7            | 60           |
| Serum albumin     | 0.63 | 61.2            | 61.6            | 3.7          |
| BTR               | 0.60 | 60.0            | 59.0            | 4.92         |
| PT                | 0.65 | 56.3            | 68.5            | 81           |
| Platelet count    | 0.60 | 47.9            | 53.9            | 9.3          |
| Total bilirubin   | 0.59 | 41.7            | 73.8            | 1.2          |
| Total cholesterol | 0.58 | 63.7            | 52.3            | 164          |
| HbA1c             | 0.53 | 26.0            | 87.5            | 4.7          |

AUC: area under the receiver operating characteristic curve, BTR: branched-chain amino acid to tyrosine ratio, PT: prothrombin time.

4. Discussion

The npRQ calculated from IC shows the ratio of carbohydrate to fat oxidation after excluding protein burning, and a lower npRQ value is shown to be an adverse predictor in LC patients [8]. However, as described earlier, IC is expensive and time-consuming [28,29]. Few clinicians are familiar with IC and thus it is not widely used in the clinical settings. Identifying markers linked to npRQ level in patients with CLDs appears to be clinically relevant, while serum Zn level can be obtained easily in the clinical settings. Zn plays an important role in various physiological functions. The current analysis was therefore done. The major strength of the study was its large sample number ($n = 586$).
The current study is, to our knowledge, the first study of its kind studying the relationship between npRQ and serum Zn level in CLD patients.

In our results, npRQ level was significantly correlated with serum Zn level for all cases, and these tendencies were confirmed for all subgroup analyses. Additionally, serum Zn level had the highest AUC for predicting npRQ < 0.85, and npRQ level was well stratified by the current Zn classification system proposed by JSCN. These results showed that serum Zn level can be helpful for assessing energy metabolism in CLDs and Zn supplementation therapy for CLD patients with decreased serum Zn level may improve energy metabolism. An optimal supply of macro and micronutrients is the mainstay of nutritional therapy in CLD patients. A recent meta-analysis demonstrated the impact of a late evening snack on energy metabolism in LC patients [34].

As described in the introduction section, Zn is essential for the catalytic activity of numerous enzymes involved in energy nutrition metabolism [15]. Decreased serum Zn level can lead to the decrease of the catalytic activity of numerous enzymes, eventually resulting in a poorer energy nutritional status (i.e., poorer npRQ). In this study, this phenomenon is more prominent in patients with Child–Pugh C as shown in Figure 3E. In our data, the correlation coefficient between npRQ and serum Zn level in patients with Child–Pugh C was 0.69, which was the highest value in our analysis. In our Child–Pugh C patients (n = 22), 14 patients (63.6%) had npRQ < 0.85 and 20 patients (90.9%) had serum Zn level < 60 µg/dL. Most Child–Pugh C patients can have experience of hepatic events such as ascites or hepatic encephalopathy which consume a lot of energy [3,4,6]. Especially in patients with far advanced LC status, serum Zn level can be helpful for predicting npRQ. While in our subgroup analyses stratified by liver disease etiology, the strongest link between npRQ and serum Zn level was observed in patients with AIH or PBC (r = 0.55, p < 0.0001). AIH or PBC patients can present higher plasma levels of lactate, acetate, acetoacetate, pyruvate and glucose which are associated with energy metabolism alterations [35,36]. These observations may be related to our results.

The correlation coefficient between npRQ and serum Zn level in non-LC patients (r = 0.29) was lower than that in LC patients (r = 0.42) in this study. In non-LC patients, 84 patients (30.3%) had npRQ < 0.85 and 43 patients (15.5%) had serum Zn level < 60 µg/dL, while in LC patients, 158 patients (51.1%) had npRQ < 0.85 and 169 patients (54.7%) had serum Zn level < 60 µg/dL. Close linkage between npRQ and serum Zn level was found with the liver disease progression.

Energy metabolism in HCC patients is poorly understood these days. In general, in patients with malignancies, tumor-secreted factors and/or host-tumor interactions result in an imbalance of energy demand and energy supply [37]. In our data, the difference of npRQ level between HCC and non-HCC patients was significant (p = 0.0074), suggesting the impact of HCC on energy metabolism. Significant correlation between npRQ and serum Zn level was found irrespective of the presence of HCC, supporting the usefulness and robustness of serum Zn level for the assessment of energy metabolism in CLDs.

The median serum Zn level was 64 µg/dL in this analysis. In LC patients, the proportion of patients with serum Zn level < 60 µg/dL was 54.4% (168/309) and in non-LC patients, that was 15.5% (43/277). Clinicians should be aware that a certain number of patients have hypozincemia even in non-LC patients. Regular follow-up for serum Zn level should be needed even in non-LC patients.

Several limitations should be acknowledged to the current analysis. Firstly, this study was a retrospective single-center study with cross-sectional analysis. Secondly, the number of patients with Child–Pugh C was small for analysis, although the strong point of the study was its large sample number (n = 586). Thirdly, the npRQ value can be affected by a patient's daily activities or daily diet, leading to bias. Finally, although npRQ level was significantly correlated with serum Zn level for all cases and for all subgroups, the r values were not so impressive except for that between serum Zn level and Child–Pugh C. Caution must therefore be applied to the interpretation of our study data. Notwithstanding, our study results showed that npRQ level in CLDs was closely linked to serum Zn level.
5. Conclusions

In conclusion, serum Zn level can be a helpful marker for npRQ in patients with CLDs. Clinicians should be aware that serum Zn level can be an alternative for energy metabolism in patients with CLDs.

Author Contributions: Data curation, H.N., R.T., H.E., K.Y., Y.I., Y.S., N.I., T.T., N.A., K.H., N.I., Y.Y., T.N. and H.I.; Formal analysis, H.N.; Methodology, H.N.; Resources, R.T.; Supervision, H.E. and S.N.; Writing—original draft, H.N.; Writing—review & editing, H.E. and S.N. All authors have read and agreed to the published version of the manuscript.

Funding: We have received no external funding.

Acknowledgments: The authors gratefully thank all medical staff in our nutritional guidance room for their help with data collection. This work was partly granted by Hyogo Innovative Challenge, Hyogo college of medicine, Japan.

Conflicts of Interest: None of the authors has any conflicts of interest to declare.

References

1. Charlton, M.R. Branched-chain amino acid enriched supplements as therapy for liver disease. J. Nutr. 2006, 136, 2955–2985. [CrossRef]
2. Moriwaki, H.; Miwa, Y.; Tajika, M.; Kato, M.; Fukushima, H.; Shiraki, M. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem. Biophys. Res. Commun. 2004, 313, 405–409. [CrossRef]
3. Stirnimann, J.; Stirnimann, G. Nutritional Challenges in Patients with Advanced Liver Cirrhosis. J. Clin. Med. 2019, 8, 1926. [CrossRef]
4. Nishikawa, H.; Osaki, Y. Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma. Hepatol. Res. 2014, 44, 149–158. [CrossRef]
5. Hanai, T.; Shiraki, M.; Nishimura, K.; Ohnishi, S.; Imai, K.; Suetugu, A.; Takai, K.; Shimizu, M.; Moriwaki, H. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition 2015, 31, 193–199. [CrossRef]
6. Plauth, M. Nutritional Intervention in Chronic Liver Failure. Visc. Med. 2019, 35, 292–298. [CrossRef]
7. Eslamparast, T.; Vandermeer, B.; Raman, M.; Gramlich, L.; Den, H.V.; Belland, D.; Ma, M.; Tandon, P. Are Predictive Energy Expenditure Equations Accurate in Cirrhosis? Nutrients 2019, 11, 334. [CrossRef]
8. Tajika, M.; Kato, M.; Mohri, H.; Miwa, Y.; Kato, T.; Ohnishi, H.; Moriwaki, H. Prognostic value of energy metabolism in patients with viral liver cirrhosis. Nutrition 2002, 18, 229–234. [CrossRef]
9. Peng, S.; Plank, L.D.; McCall, J.L.; Gillanders, L.K.; McIlroy, K.; Gane, E.J. Body composition, muscle function, and energy expenditure in patients with liver cirrhosis: A comprehensive study. Am. J. Clin. Nutr. 2007, 85, 1257–1266. [CrossRef]
10. Sakai, Y.; Iwata, Y.; Enomoto, H.; Saito, M.; Yoh, K.; Ishii, A.; Takashima, T.; Aizawa, N.; Ikeda, N.; Tanaka, H.; et al. Two randomized controlled studies comparing the nutritional benefits of branched-chain amino acid (BCAA) granules and a BCAA-enriched nutrient mixture for patients with esophageal varices after endoscopic treatment. J. Gastroenterol. 2015, 50, 109–118. [CrossRef]
11. Shiraki, M.; Nishiguchi, S.; Saito, M.; Fukuzawa, Y.; Mizuta, T.; Kaibori, M.; Hanai, T.; Nishimura, K.; Shimizu, M.; Tsurumi, H.; et al. Nutritional status and quality of life in current patients with liver cirrhosis as assessed in 2007–2011. Hepatol. Res. 2013, 43, 106–112. [CrossRef] [PubMed]
12. Takata, R.; Nishikawa, H.; Enomoto, H.; Yoh, K.; Iwata, Y.; Sakai, Y.; Kishino, K.; Ikeda, N.; Takashima, T.; Aizawa, N.; et al. Association between Albumin-Bilirubin Grade and Non-Protein Respiratory Quotient in Patients with Chronic Liver Diseases. J. Clin. Med. 2019, 8, 1485. [CrossRef] [PubMed]
13. Nishikawa, H.; Enomoto, H.; Yoh, K.; Iwata, Y.; Sakai, Y.; Kishino, K.; Ikeda, N.; Takashima, T.; Aizawa, N.; Takata, R.; et al. Combined Albumin-Bilirubin Grade and Skeletal Muscle Mass as a Predictor in Liver Cirrhosis. J. Clin. Med. 2019, 8, 782. [CrossRef] [PubMed]
14. Grüngreif, K. Zinc in liver disease. J. Trace Elem. Exp. Med. 2002, 15, 67–78. [CrossRef]
15. Evans, S.A.; Overton, J.M.; Alshingiti, A.; Levenson, C.W. Regulation of metabolic rate and substrate utilization by zinc deficiency. Metabolism 2004, 53, 727–732. [CrossRef]
16. Livingstone, C. Zinc: Physiology, deficiency, and parenteral nutrition. Nutr. Clin. Pract. 2015, 30, 371–382. [CrossRef]
17. Santos, H.O.; Teixeira, F.J.; Schoenfeld, B.J. Dietary vs. pharmacological doses of zinc: A clinical review. *Clin. Nutr.* 2019. [CrossRef]

18. Skrajnowska, D.; Bobrowska-Korczak, B. Role of Zinc in Immune System and Anti-Cancer Defense Mechanisms. *Nutrients* 2019, 11, 2273. [CrossRef]

19. Glutsch, V.; Hamm, H.; Goebeler, M. Zinc and skin: An update. *J. Dtsch. Dermatol. Ges.* 2019, 17, 589–596. [CrossRef]

20. Koop, A.H.; Mousa, O.Y.; Pham, L.E.; Corral-Hurtado, J.E.; Pungpapong, S.; Keaveny, A.P. An Argument for Vitamin D, A, and Zinc Monitoring in Cirrhosis. *Ann. Hepatol.* 2018, 17, 920–932. [CrossRef]

21. Martínez-Peinado, M.; Rueda-Robles, A.; Nogueras-López, F.; Villalón-Mir, M.; Oliveras-López, M.J.; Navarro-Alarcón, M. Serum zinc and copper concentrations and ratios in cirrhotic patients: Correlation with severity index. *Nutr. Hosp.* 2018, 35, 627–632. [CrossRef] [PubMed]

22. Skalny, A.V.; Skalnaya, M.G.; Grabeklis, A.R.; Skalnaya, A.A.; Tinkov, A.A. Zinc deficiency as a mediator of toxic effects of alcohol abuse. *Eur. J. Nutr.* 2018, 57, 2313–2322. [CrossRef] [PubMed]

23. Katayama, K.; Saito, M.; Kawaguchi, T.; Endo, R.; Sawara, K.; Nishiguchi, S.; Kato, A.; Kohgo, H.; Suzuki, K.; Sakaida, I.; et al. Effect of zinc on liver cirrhosis with hyperammonemia: A preliminary randomized, placebo-controlled double-blind trial. *Nutrition* 2014, 30, 1409–1414. [CrossRef] [PubMed]

24. Kazunari, I.; Hirayuki, E.; Shuhei, N.; Nobuhiro, A.; Yoshiyuki, S.; Yoshinori, I.; Hironori, T.; Naoto, I.; Tomoyuki, T.; Masaki, S.; et al. Serum zinc value in patients with hepatitis virus-related chronic liver disease: Association with the histological degree of liver fibrosis and with the severity of varices in compensated cirrhosis. *J. Clin. Biochem. Nutr.* 2014, 55, 147–152.

25. Grünreiff, K.; Reinhold, D.; Wedemeyer, H. The role of zinc in liver cirrhosis. *Ann. Hepatol.* 2016, 15, 7–16. [CrossRef]

26. Nishikawa, H.; Enomoto, H.; Yoh, K.; Iwata, Y.; Sakai, Y.; Kishino, K.; Ikeda, N.; Takashima, T.; Aizawa, N.; Takata, R.; et al. Serum Zinc Concentration and Sarcopenia: A Close Linkage in Chronic Liver Diseases. *J. Clin. Med.* 2019, 8, 336. [CrossRef]

27. Nishikawa, H.; Shiraki, M.; Hiramatsu, A.; Moriya, K.; Hino, K.; Nishiguchi, S. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. *Hepatol. Res.* 2016, 46, 951–963. [CrossRef]

28. Nishikawa, H.; Enomoto, H.; Iwata, Y.; Kishino, K.; Shimono, Y.; Hasegawa, K.; Nakano, C.; Takata, R.; Ishii, A.; Nishimura, T.; et al. Prognostic significance of nonprotein respiratory quotient in patients with liver cirrhosis. *Medicine (Baltimore)* 2017, 96, e5800. [CrossRef]

29. Nishikawa, H.; Enomoto, H.; Yoh, K.; Iwata, Y.; Hasegawa, K.; Nakano, C.; Takata, R.; Kishino, K.; Shimono, Y.; Sakai, Y.; et al. Serum hyaluronic acid predicts protein-energy malnutrition in chronic hepatitis C. *Medicine (Baltimore)* 2016, 95, e3920. [CrossRef]

30. Dickerson, R.N.; Tidwell, A.C.; Minard, G.; Croce, M.A.; Brown, R.O. Predicting total urinary nitrogen excretion from urinary urea nitrogen excretion in multiple-trauma patients receiving specialized nutritional support. *Nutrition* 2005, 21, 332–338. [CrossRef]

31. Mallbran, M.L.; Huygh, J.; Dabrowski, W.; De Waele, J.J.; Staelsens, A.; Wauters, J. The use of bio-electrical impedance analysis (BIA) to guide fluid management, resuscitation and deresuscitation in critically ill patients: A bench-to-bedside review. *Anaesthesiol. Intensive Ther.* 2014, 46, 381–391. [CrossRef] [PubMed]

32. Fukui, H.; Saito, H.; Ueno, Y.; Uto, H.; Obara, K.; Sakaida, I.; Shibuya, A.; Seike, M.; Nagoshi, S.; Segawa, M.; et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015. *J. Gastroenterol.* 2016, 51, 629–650. [CrossRef] [PubMed]

33. Nishikawa, H.; Enomoto, H.; Yoh, K.; Iwata, Y.; Sakai, Y.; Kishino, K.; Ikeda, N.; Takashima, T.; Aizawa, N.; Takata, R.; et al. Serum Zinc Level Classification System: Usefulness in Patients with Liver Cirrhosis. *J. Clin. Biochem. Nutr.* 2019, 6, 147–152. [CrossRef] [PubMed]

34. Guo, Y.J.; Tian, Z.B.; Jiang, N.; Ding, X.L.; Tao, T.; Jing, X. Effects of Late Evening Snack on Cirrhotic Patients: A Systematic Review and Meta-Analysis. *Gastroenterol. Res. Pract.* 2018, 2018, 9189062. [CrossRef] [PubMed]

35. Wang, J.B.; Pu, S.B.; Sun, Y.; Li, Z.F.; Niu, M.; Yan, X.Z.; Zhao, Y.L.; Wang, L.F.; Qin, X.M.; Ma, Z.J.; et al. Metabolomic Profiling of Autoimmune Hepatitis: The Diagnostic Utility of Nuclear Magnetic Resonance Spectroscopy. *J. Proteome Res.* 2014, 13, 3792–3801. [CrossRef] [PubMed]
36. Vignoli, A.; Orlandini, B.; Tenori, L.; Biagini, M.R.; Milani, S.; Renzi, D.; Luchinat, C.; Calabrò, A.S. Metabolic Signature of Primary Biliary Cholangitis and Its Comparison with Celiac Disease. *J. Proteome Res.* 2019, 18, 1228–1236. [CrossRef]

37. Rohm, M.; Zeigerer, A.; Machado, J.; Herzig, S. Energy metabolism in cachexia. *EMBO Rep.* 2019, 20, e47258. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).